BioRestorative Therapies, Inc.
BRTXBioRestorative Therapies, Inc. in brief
BioRestorative Therapies, Inc. is a listed company in the Healthcare sector, based in Melville, New York, USA. Its market value was $6 M on 1 August 2026, which makes it the 26,621st largest listed company in the world and the 4,372nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $14 M. It employs about 14 people. Its largest product and service lines by sales in 2025 were Royalty (17%). Its shares trade under the symbol BRTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About BioRestorative Therapies, Inc.
We were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we reincorporated in Nevada.
We are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100. In March 2022, a United States patent issued in our Disc/Spine Program. We are conducting a Phase 2 clinical trial investigating the use of BRTX-100 in the treatment of chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration, or the FDA, Investigational New Drug, or IND, clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
From the company's annual report filed with the US SEC: read the report
BioRestorative Therapies, Inc. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed BioRestorative Therapies, Inc.Formerly Stem Cell Assurance, Inc..
- 2024
- 💰Record revenue of $0 millionFY2024, the highest of the 8 years on record.
Events of BioRestorative Therapies, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,536 (Jan 2022) · #5,529 (Dec 2022) · #5,392 (Jul 2023) · #4,557 (Jan 2024) · #2,486 (Mar 2026) · #4,099 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 16.7×
- Price / book
- 16.7×
- Free cash flow yield
- -181.8%
- Net margin (TTM)
- -3069.4%
- Operating margin
- -4347.2%
- Return on equity
- -3069.4%
- Liabilities / assets
- 91.2%
- Net debt
- $-21M
- Revenue growth
- -10.0%
- R&D / revenue
- 2802.8%
- Revenue per employee
- $26 K
- Profit per employee
- $-1.0 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -10.0% | $-16M | $-14M | -3955.6% |
| Dec 2024 | $0M | +166.7% | $-12M | $-9M | -2245.0% |
| Dec 2023 | $0M | +25.0% | $-15M | $-10M | -6946.7% |
| Dec 2022 | $0M | +140.0% | $-19M | $-13M | -11016.7% |
| Dec 2021 | $0M | -37.5% | $-26M | $-44M | -88600.0% |
| Dec 2020 | $0M | -38.5% | $-3M | $-11M | -14087.5% |
| Dec 2019 | $0M | +18.2% | $-8M | $-15M | -11269.2% |
| Dec 2018 | $0M | — | $-8M | $-13M | -11381.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | $0M | $-11M | $-1.58 | — |
| Dec 2024 | $-8M | $0M | $-8M | $-1.16 | — |
| Dec 2023 | $-6M | $0M | $-7M | $-2.47 | — |
| Dec 2022 | $-6M | $0M | $-6M | $-3.65 | — |
| Dec 2021 | $-3M | $0M | $-3M | $-37.30 | — |
| Dec 2020 | $-2M | — | — | $-28.56 | — |
| Dec 2019 | $-7M | $0M | $-7M | $-0.66 | — |
| Dec 2018 | $-5M | $0M | $-5M | $-1.64 | — |
Quarterly results
Latest quarter to Mar 2026: revenue $0M (0.0% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2026.
SEC filings
- Nov 12, 20268-KCurrent reportDirectors or officers changed
- Oct 9, 20268-KCurrent reportDirectors or officers changed
- Sep 11, 20268-KCurrent reportDirectors or officers changed
- Sep 10, 20268-K/ACurrent report (amended)Auditor change · Other events
- Sep 2, 20268-KCurrent reportBylaws amended · Regulation FD disclosure
- Sep 2, 20268-KCurrent reportAuditor change · Directors or officers changed
- Aug 25, 20268-KCurrent reportListing notice
- Aug 14, 20268-KCurrent reportOther events
- Jul 16, 20268-KCurrent reportDirectors or officers changed
- Jun 12, 20268-KCurrent reportDirectors or officers changed
- Jun 12, 20268-KCurrent reportMaterial agreement · Directors or officers changed
- May 29, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
Official filings of BioRestorative Therapies, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-16 M
- Net income
- $-14 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $4 M
- Total liabilities
- $4 M
- Total equity
- $0 M
As of December-2025
Top 14 institutional investors in BioRestorative Therapies, Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Citadel Advisors LLC | 30,951 | New | $0 M | Nov 16, 2026 |
| 2 | Jane Street Group, LLC | 27,156 | New | $0 M | Nov 12, 2026 |
| 3 | HRT Financial LP | 14,194 | New | $0 M | Nov 13, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 9,065 | New | $0 M | Nov 13, 2026 |
| 5 | UBS Group AG | 3,422 | New | $0 M | Nov 10, 2026 |
| 6 | Vanguard Capital Management LLC | 2,134 | New | $0 M | Nov 13, 2026 |
| 7 | Tower Research Capital LLC (TRC) | 864 | New | $0 M | Nov 16, 2026 |
| 8 | Osaic Holdings, Inc. | 100 | New | $0 M | Nov 12, 2026 |
| 9 | SBI Securities Co., Ltd. | 91 | New | $0 M | Oct 22, 2026 |
| 10 | Rossby Financial, LCC | 5 | New | $0 M | Nov 5, 2026 |
| 11 | TD Waterhouse Canada Inc. | 2 | New | $0 M | Oct 16, 2026 |
| 12 | Citigroup Inc | 1 | New | $0 M | Nov 4, 2026 |
| 13 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1 | New | $0 M | Nov 16, 2026 |
| 14 | Parallel Advisors, LLC | 1 | New | $0 M | Nov 3, 2026 |
Mutual funds holding BioRestorative Therapies, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 193,321 | $0 M | — | <0.01% | +555% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,405 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,558 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,862 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at BioRestorative Therapies, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lance AlstodtPresident, CEO, COB, Director, 10% owner | Grant or award | +15,625 | $1.600 | $25 K | 187,497 | Form 4 |
| filed | Francisco SilvaVP of Research and Development, Director | Grant or award | +11,719 | $1.600 | $19 K | 171,384 | Form 4 |
| filed | Dale Broadrick10% owner | Sell | -1,112 | $1.580 | $2 K | 445,933 | Form 4 |
| filed | Francisco SilvaVP of Research and Development, Director | Buy | +6,600 | $1.250 | $8 K | 155,759 | Form 4 |
| filed | Francisco SilvaVP of Research and Development, Director | Buy | +476 | $1.130 | $538 | 147,927 | Form 4 |
| filed | Francisco SilvaVP of Research and Development, Director | Buy | +1,232 | $1.170 | $1 K | 149,159 | Form 4 |
| filed | Francisco SilvaVP of Research and Development, Director | Shares withheld for tax | -17,193 | $1.390 | $24 K | 147,451 | Form 4 |
| filed | Lance AlstodtPresident, CEO, COB, Director | Shares withheld for tax | -17,633 | $1.390 | $25 K | 171,872 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: BioRestorative Therapies, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2026 | Q1 2026 | $0M |
| Q1 2014 | Q1 2014 | $0M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $0M |
| Q2 2013 | Q2 2013 | $0M |
| Q1 2013 | Q1 2013 | $0M |
| Q4 2012 | Q4 2012 | $0M |
| Q3 2012 | Q3 2012 | $0M |
| Q2 2012 | Q2 2013 | $0M |
| Q1 2012 | Q1 2013 | $0M |
| Q4 2011 | Q4 2011 | $0M |
| Q3 2011 | Q3 2011 | $0M |
| Q4 2010 | Q4 2011 | $0M |
Trading halts
- 2026-09-04 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 4,516 shares at $1.58
- : 963 shares at $1.43
- : 48 shares at $1.49
- : 479 shares at $1.62
- : 97 shares at $1.53
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BioRestorative Therapies, Inc. scorecard#
Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.58 vs -1.16Diluted EPS -1.58 in fiscal 2025 against -1.16 the year before (report's currency).
- ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$11 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-320.4%-320.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.84 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-70.08Z-score -70.08 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
BioRestorative Therapies, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.4−10.3%100% | 0.4+175%100% | 0.1+21.7%100% | 0.1+160%100% | 0.0−40.3%100% | 0.1−40.8%100% | 0.1+17.1%100% | 0.1+37.0%100% | 0.1+123%100% | 0.0—100% | |
| Cost of revenue | 0.0−15.1%6.6% | 0.0—7.0% | — | — | — | — | — | — | — | 0.0—0.3% | |
| Gross profit | 0.3−9.9%93.4% | 0.4+156%93.0% | 0.1—100% | — | — | — | — | — | 0.1+123%100% | 0.0—99.7% | |
| Research and development | 10+50.5%2806% | 6.7r5.3+66.2%1673% | 4.0+14.8%2767% | 3.5+382%2933% | 0.7−16.9%1585% | 0.9−49.1%1139% | 1.7+13.8%1325% | 1.5−29.7%1363% | 2.2−25.4%2657% | 2.9—7932% | |
| General and administrative | 5.9+12.8%1637% | 5.2r6.6−53.9%1302% | 11−27.3%7772% | 16−39.2%13005% | 26r26+1334%55706% | 1.8−61.2%2320% | 4.6+14.5%3543% | 4.0+3.1%3624% | 3.9+20.3%4819% | 3.2r3.3—8927% | |
| Operating expenses | 16+34.0%4443% | 12−22.4%2975% | 15−19.5%10539% | 19−27.5%15938% | 26+832%57291% | 2.8−67.0%3674% | 8.6+10.4%6586% | 7.8−8.2%6990% | 8.5+8.1%10439% | 7.8r7.8—21514% | |
| Operating income | −16—−4350% | −12—−2882% | −15—−10439% | −19—−15838% | −26—−57191% | −2.8—−3574% | −8.4—−6486% | −7.6—−6890% | −8.4—−10339% | −7.8r−7.8—−21414% | |
| Interest and finance income | 0.3−56.6%75.2% | 0.6+9.6%156% | 0.6+649%390% | 0.1—63.4% | — | — | — | — | — | — | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0.2+2049%257% | 0.0—26.6% | |
| Net interest income | 0.3−56.8%74.0% | 0.6+11.5%154% | 0.6+4641%379% | 0.0—9.7% | −1.8—−3946% | — | — | — | — | — | |
| Other non-operating income (expense) | 1.4−45.4%391% | 2.6−46.4%642% | 4.8r0.8−16.5%3294% | 5.8r0.5—4801% | −18—−39120% | −8.5—−11066% | −6.2—−4781% | −4.9—−4388% | −1.1—−1321% | −0.9r−0.8—−2341% | |
| Income before tax | −14—−3948% | −9.0—−2239% | — | — | — | — | — | — | −9.4—−11660% | −8.6—−23755% | |
| Net income attributable to shareholders | −14—−3959% | −9.0—−2239% | −10r−14—−7145% | −13r−18—−11037% | −44—−96312% | −11—−14640% | −15—−11268% | −13—−11277% | −9.4—−11660% | −8.6—−23755% | |
| Earnings per share, basic | -1.58—— | -1.16—— | -2.47r-3.42—— | -3.65r-5.11—— | -37.30—— | -28.56r-0.01—— | -0.66—— | -1.64—— | -1.74—— | -2.10—— | |
| Earnings per share, diluted | -1.58—— | -1.16—— | -2.47r-3.42—— | -3.65r-5.11—— | -37.30—— | -28.56r-0.01—— | -0.66—— | -1.64—— | -1.74—— | -2.10—— | |
| Shares, weighted average (basic) | 9.0+15.8%— | 7.8+84.1%— | 4.2+16.6%— | 3.6+205%— | 1.2—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 9.0+15.8%— | 7.8+84.1%— | 4.2+16.6%— | 3.6+205%— | 1.2+201%— | 0.4r1,579−98.2%— | 22+192%— | 7.6+40.7%— | 5.4+32.1%— | 4.1—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.5+176%37.0% | 0.5−38.0%4.5% | 0.9−48.4%7.0% | 1.7r1.7−91.8%10.4% | 21+586%93.6% | 3.1+184071%70.5% | 0.0−98.6%0.1% | 0.1−74.0%9.9% | 0.5+1319%25.7% | 0.0—2.0% | |
| Short-term investments | 1.4−85.8%35.3% | 10+0.0%82.9% | 10−21.9%80.7% | 13r13—79.3% | — | — | — | — | — | — | |
| Receivables | 0.0−91.8%0.4% | 0.2+876%1.5% | 0.0+20.6%0.2% | 0.0+220%0.1% | 0.0−70.6%0.0% | 0.0−46.9%0.4% | 0.0+10.3%2.2% | 0.0−23.7%2.4% | 0.0+533%2.2% | 0.0—0.4% | |
| Other current assets | 0.2−24.5%4.1% | 0.2−26.9%1.8% | 0.3−15.9%2.4% | 0.4−16.8%2.2% | 0.4—1.9% | — | — | 0.0+14.8%2.9% | 0.0−15.6%1.7% | 0.0r0.0—2.3% | |
| Current assets | 3.1−71.9%76.9% | 11−2.2%90.8% | 11−24.7%90.3% | 15−29.5%92.1% | 21+574%95.6% | 3.2+4528%73.3% | 0.1−62.0%4.7% | 0.2−65.2%15.2% | 0.5+608%29.6% | 0.1r0.1—4.6% | |
| Property, plant and equipment | 0.4−1.1%8.8% | 0.4+1.9%3.0% | 0.4+36.4%2.8% | 0.3+587%1.6% | 0.0+73.4%0.2% | 0.0−68.0%0.5% | 0.1−61.0%4.7% | 0.2−46.5%14.7% | 0.3−35.5%18.6% | 0.5—32.2% | |
| Right-of-use (leased) assets | — | — | 0.2−37.4%1.2% | 0.2−32.4%1.5% | 0.4−24.5%1.6% | 0.5−19.7%10.9% | 0.6—40.2% | — | — | — | |
| Other intangible assets | 0.5−14.4%13.1% | 0.6−12.6%5.1% | 0.7−11.2%5.7% | 0.8+36.2%4.9% | 0.6−11.2%2.6% | 0.7−10.1%15.3% | 0.7−9.2%50.4% | 0.8−8.4%68.3% | 0.9−7.8%50.5% | 1.0—61.0% | |
| Total assets | 4.1−66.8%100% | 12−2.6%100% | 13−23.3%100% | 16−26.8%100% | 22+417%100% | 4.3+196%100% | 1.5+23.0%100% | 1.2−32.2%100% | 1.8+11.3%100% | 1.6—100% | |
| Accounts payable | 1.3+178%32.9% | 0.5+155%3.9% | 0.2+10.8%1.5% | 0.2+236%1.0% | 0.1−57.2%0.2% | 0.1−93.9%2.7% | 2.0+3.2%133% | 1.9−22.9%159% | 2.5+7.5%140% | 2.3—145% | |
| Current liabilities | 3.7−0.7%91.3% | 3.7+43.8%30.5% | 2.6r1.1−56.4%20.7% | 6.0r0.4+1544%36.4% | 0.4−65.2%1.6% | 1.0−92.4%24.0% | 14+48.3%936% | 9.3+10.8%776% | 8.4+42.9%475% | 5.8—370% | |
| Lease liabilities (non-current) | — | — | — | 0.2−46.2%1.0% | 0.3−17.0%1.3% | 0.4−30.3%8.4% | 0.5—35.6% | — | — | — | |
| Total liabilities | — | 3.7+43.8%30.5% | 2.6r1.1−57.6%20.7% | 6.1r0.6+617%37.4% | 0.9−84.9%3.8% | 5.7−60.1%131% | 14+44.8%971% | 9.8+14.4%825% | 8.6+30.6%489% | 6.6—416% | |
| Retained earnings | −170—−4165% | −156—−1268% | −147r−167—−1163% | −136r−153—−829% | −134—−597% | −90—−2067% | −79—−5358% | −64—−5361% | −51—−2923% | −42—−2656% | |
| Shareholders' equity | 0.4−95.8%8.7% | 8.5−14.7%69.5% | 10r12−2.8%79.3% | 10r16−4.6%62.6% | 11r22—48.0% | −1.3—−30.6% | −13—−871% | −8.6—−725% | −6.8—−389% | −5.0—−316% | |
| Total liabilities and equity | 4.1−66.8%100% | 12−2.6%100% | 13−23.3%100% | 16−26.8%100% | 22+417%100% | 4.3+196%100% | 1.5+23.0%100% | 1.2−32.2%100% | 1.8+11.3%100% | 1.6—100% | |
| Shares outstanding | 8.9+28.3%— | 6.9+47.0%— | 4.7+28.0%— | 3.7+4.5%— | 3.5+392%— | 0.7r2,862−99.1%— | 78+564%— | 12+91.9%— | 6.1+30.1%— | 4.7—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2+11.1%58.4% | 0.2+14.1%47.1% | 0.2+37.5%114% | 0.1+35.3%101% | 0.1−26.6%194% | 0.1−44.2%158% | 0.2−9.6%167% | 0.2−7.3%217% | 0.3+0.3%320% | 0.3—711% | |
| Share-based compensation | 3.3+18.2%925% | 2.8−63.9%701% | 7.8−38.3%5338% | 13−45.4%10528% | 23+3241%50237% | 0.7−58.3%898% | 1.7−30.9%1276% | 2.4−33.4%2162% | 3.6+41.9%4445% | 2.5—6978% | |
| Cash from operating activities | −11—−2999% | −8.2—−2052% | −6.4—−4410% | −5.9r−5.9—−4936% | −3.3—−7239% | −2.0—−2551% | −6.9—−5322% | −5.1—−4599% | −3.9—−4758% | −5.0—−13761% | |
| Capital expenditure | −0.1—−32.3% | −0.1—−26.5% | −0.2—−117% | −0.3—−221% | −0.0—−66.6% | — | −0.0—−27.4% | −0.0—−11.6% | −0.0—−4.5% | −0.2—−519% | |
| Intangible assets bought | — | — | — | −0.2—−146% | — | — | — | — | — | — | |
| Cash from investing activities | 8.9+1629%2474% | 0.5−84.2%128% | 3.3—2230% | −13r−13—−11185% | −0.0—−66.6% | — | −0.0—−27.4% | −0.0—−11.6% | −0.0—−4.5% | −0.2—−519% | |
| Debt repaid | — | — | — | — | — | — | — | — | −0.1—−148% | −0.3—−886% | |
| Shares issued | 3.1—861% | — | 0.5r1.9—339% | — | — | — | — | — | — | — | |
| Shares bought back | 0—0.0% | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 2.9−61.3%794% | 7.4+214%1840% | 2.3r2.4—1611% | — | 21+324%46354% | 5.0r5.5−26.5%6529% | 6.8+43.0%5260% | 4.8+11.8%4309% | 4.3−15.4%5281% | 5.1—13909% | |
| Change in cash | 1.0—268% | −0.3—−83.9% | −0.8r−0.8—−569% | −19r−19−208%−16121% | 18+486%39048% | 3.1—3978% | −0.1—−89.1% | −0.3−180%−301% | 0.4—518% | — | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.4−8.5%100% | 0.0−7.3%100% | 0.0*−54.7%100% | 0.0−94.9%100% | 0.3+240%100% | 0.0−28.6%100% | 0.0*+124%100% | 0.2+661%100% | 0.1+38.1%100% | 0.0—100% | 0.0*—100% | 0.0—100% | 0.1—100% | |
| Cost of revenue | 0.0−8.6%7.9% | 0.0+154%31.9% | 0.0*−51.0%8.3% | 0.0−42.1%89.6% | 0.0+34.5%2.9% | 0.0—11.6% | 0.0*—7.7% | 0.0—7.8% | 0.0—7.3% | — | — | — | — | |
| Gross profit | 0.3−8.5%92.1% | 0.0−28.5%68.1% | 0.0*−55.0%91.7% | 0.0−99.4%10.4% | 0.3+257%97.1% | 0.0−36.9%88.4% | 0.0*+107%92.3% | 0.2+601%92.2% | 0.1+28.1%92.7% | 0.0—100% | 0.0*—100% | 0.0—100% | 0.1—100% | |
| Research and development | 9.4+29.2%2619% | 1.9−27.2%8314% | 2.6*+54.3%13404% | 2.6+78.5%21989% | 2.2+53.1%734% | 2.6r1.7+150%10588% | 1.7r1.7*+56.1%3931% | 1.5r1.3+79.5%622% | 1.5r1.3+61.0%1632% | 1.1—3023% | 1.1r0.7*—5648% | 0.8r0.9—2638% | 0.9r1.0—1400% | |
| General and administrative | 5.2−3.3%1448% | 1.5−32.4%6367% | 1.2*+18.3%6205% | 1.1+6.3%9453% | 1.4+25.2%453% | 2.2r3.1−29.3%8731% | 1.0r1.1*−52.2%2374% | 1.0r1.2−54.9%449% | 1.1r1.3−51.8%1232% | 3.1—8817% | 2.1r2.6*—11139% | 2.3r2.3—7574% | 2.3r2.2—3532% | |
| Operating expenses | 15+15.4%4067% | 3.4−29.6%14681% | 3.8*+40.8%19608% | 3.7+48.3%31443% | 3.6+41.1%1187% | 4.8+16.5%19319% | 2.7*−15.7%6305% | 2.5−20.2%1071% | 2.6−19.8%2864% | 4.1—11841% | 3.2*—16787% | 3.1—10212% | 3.2—4932% | |
| Operating income | −14—−3975% | −3.4—−14613% | −3.8*—−19517% | −3.7—−31432% | −3.3—−1090% | −4.8—−19230% | −2.7*—−6213% | −2.3—−979% | −2.5—−2771% | −4.1—−11741% | −3.2*—−16687% | −3.1—−10112% | −3.1—−4832% | |
| Interest and finance income | 0.2−69.8%48.6% | 0.0−94.1%26.2% | 0.0*−73.6%177% | 0.1*−64.1%503% | 0.1*−58.0%24.3% | 0.1−32.2%411% | 0.1*−67.3%303% | 0.2*—70.8% | 0.2*+23.4%197% | 0.2—433% | 0.4*—2084% | — | 0.1*—220% | |
| Net interest income | — | — | 0.0*−70.9%176% | 0.1−63.6%489% | 0.1−58.0%24.4% | 0.1−38.5%400% | 0.1*−68.4%275% | 0.2+157%67.9% | 0.2+82.9%197% | 0.2—465% | 0.4*—1949% | 0.1—201% | 0.1—149% | |
| Other non-operating income (expense) | 3.2+1911%885% | 1.2—5314% | 0.6*−41.4%3151% | 0.7−43.9%5684% | 0.6—214% | −0.5−128%−2129% | 1.1*+15.0%2434% | 1.2−84.8%512% | −1.6—−1751% | 1.9—5389% | 0.9r0.4*—4750% | 7.9r0.2—25644% | −2.6r0.1—−4020% | |
| Net income attributable to shareholders | −11—−3090% | −2.2—−9298% | −3.2*—−16365% | −3.0—−25748% | −2.7—−876% | −5.3—−21359% | −1.6*—−3779% | −1.1−123%−467% | −4.0—−4521% | −2.2—−6352% | −2.3r−2.8*—−11938% | 4.8r−2.9—15532% | −5.7r−3.0—−8852% | |
| Earnings per share, basic | — | -0.12—— | — | -0.33—— | -0.30—— | -0.64—— | — | -0.13−113%— | -0.50—— | -0.33—— | — | 1.04r-0.64—— | -1.47r-0.77—— | |
| Earnings per share, diluted | — | -0.12—— | — | -0.33—— | -0.30—— | -0.64—— | — | -0.13−133%— | -0.50—— | -0.33—— | — | 0.39r-0.64—— | -1.47r-0.77—— | |
| Shares, weighted average (basic) | 18+112%— | 18+112%— | — | 9.1+12.2%— | 8.7+7.6%— | 8.4+25.3%— | — | 8.1+77.7%— | 8.1+109%— | 6.7—— | — | 4.6—— | 3.9—— | |
| Shares, weighted average (diluted) | 18+112%— | 18+112%— | — | 9.1+12.2%— | 8.7+7.6%— | 8.4+25.3%— | — | 8.1−34.1%— | 8.1+109%— | 6.7—— | — | 12r4.6—— | 3.9—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.1—67.1% | 3.1+153%67.1% | 1.5+176%37.0% | 0.6−59.6%10.7% | 1.6−30.9%18.3% | 1.2+6.2%11.9% | 0.5−38.0%4.5% | 1.5−38.9%10.2% | 2.3+26.3%14.0% | 1.2—6.4% | 0.9—7.0% | 2.4—17.7% | 1.8—13.4% | |
| Short-term investments | 0.5—10.3% | 0.5−93.9%10.3% | 1.4−85.8%35.3% | 3.9−66.5%68.9% | 5.8−53.1%68.4% | 7.9−48.3%76.3% | 10+0.0%82.9% | 12+18.3%79.6% | 12+26.4%77.1% | 15—85.0% | 10—80.7% | 9.8—71.0% | 9.8—73.9% | |
| Receivables | 0.0—0.3% | 0.0−46.8%0.3% | 0.0−91.8%0.4% | 0.0−91.9%0.2% | 0.0−45.3%0.2% | 0.0−28.6%0.2% | 0.2+876%1.5% | 0.2+320%1.1% | 0.0+9.6%0.2% | 0.0—0.2% | 0.0—0.2% | 0.0—0.3% | 0.0—0.2% | |
| Other current assets | 0.2—4.2% | 0.2−10.6%4.2% | 0.2−24.5%4.1% | 0.2−12.6%3.6% | 0.2−31.8%2.4% | 0.2−31.4%2.1% | 0.2−26.9%1.8% | 0.2−28.3%1.6% | 0.3−26.7%1.8% | 0.3—1.8% | 0.3—2.4% | 0.3—2.4% | 0.4—3.0% | |
| Current assets | 3.8—81.9% | 3.8−59.4%81.9% | 3.1−71.9%76.9% | 4.7−65.2%83.4% | 7.6−49.4%89.2% | 9.4−44.2%90.6% | 11−2.2%90.8% | 14+7.2%92.7% | 15+24.6%93.1% | 17—93.4% | 11—90.3% | 13—91.3% | 12—90.6% | |
| Property, plant and equipment | 0.3—7.1% | 0.3−11.1%7.1% | 0.4−1.1%8.8% | 0.3−18.2%5.5% | 0.3−1.8%4.0% | 0.4+1.4%3.6% | 0.4+1.9%3.0% | 0.4+23.5%2.6% | 0.3+10.1%2.1% | 0.4—2.0% | 0.4—2.8% | 0.3—2.2% | 0.3—2.4% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | 0.0−74.3%0.3% | 0.1−57.5%0.5% | 0.1—0.6% | 0.2—1.2% | 0.2—1.1% | 0.2—1.4% | |
| Other intangible assets | 0.5—11.0% | 0.5−14.9%11.0% | 0.5−14.4%13.1% | 0.6−13.9%9.9% | 0.6−13.4%6.8% | 0.6−13.0%5.8% | 0.6−12.6%5.1% | 0.6−12.2%4.4% | 0.7−11.8%4.1% | 0.7—3.9% | 0.7—5.7% | 0.7—5.3% | 0.8—5.7% | |
| Total assets | 4.6—100% | 4.6−55.1%100% | 4.1−66.8%100% | 5.6−61.3%100% | 8.5−47.2%100% | 10−42.5%100% | 12−2.6%100% | 15+5.6%100% | 16+21.2%100% | 18—100% | 13—100% | 14—100% | 13—100% | |
| Accounts payable | 0.7—14.4% | 0.7+11.2%14.4% | 1.3+178%32.9% | 0.9+114%15.2% | 0.6+182%7.2% | 0.6+160%5.8% | 0.5+155%3.9% | 0.4+76.5%2.8% | 0.2−21.8%1.3% | 0.2—1.3% | 0.2—1.5% | 0.2—1.6% | 0.3—2.1% | |
| Current liabilities | 1.6—34.8% | 1.6−61.4%34.8% | 3.7−0.7%91.3% | 3.4−25.0%60.9% | 3.7−31.0%43.1% | 4.2+21.3%40.5% | 3.7+43.8%30.5% | 4.6+52.8%31.4% | 5.3−49.7%33.0% | 3.4—19.2% | 2.6r1.1—20.7% | 3.0r0.9—21.7% | 11r0.8—79.5% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | — | 0.0—0.3% | 0.1—0.6% | |
| Total liabilities | — | — | — | — | 3.7−31.0%43.1% | 4.2+21.3%40.5% | 3.7+43.8%30.5% | 4.6+50.7%31.4% | 5.3−50.1%33.0% | 3.4—19.2% | 2.6r1.1—20.7% | 3.0r1.0—22.0% | 11r0.9—80.1% | |
| Retained earnings | −172—−3708% | −172—−3708% | −170—−4165% | −167—−2955% | −164—−1922% | −161—−1559% | −156—−1268% | −154—−1057% | −153—−949% | −149—−830% | −147r−167—−1163% | −144r−164—−1046% | −149r−161—−1122% | |
| Shareholders' equity | 3.0—65.2% | 3.0−50.8%65.2% | 0.4−95.8%8.7% | 2.2−77.9%39.1% | 4.8−55.1%56.9% | 6.1−57.6%59.5% | 8.5−14.7%69.5% | 10.0−7.1%68.6% | 11+308%67.0% | 15—80.8% | 10r12—79.3% | 11r13—78.0% | 2.6r12—19.9% | |
| Total liabilities and equity | 4.6—100% | 4.6−55.1%100% | 4.1−66.8%100% | 5.6−61.3%100% | 8.5−47.2%100% | 10−42.5%100% | 12−2.6%100% | 15+5.6%100% | 16+21.2%100% | 18—100% | 13—100% | 14—100% | 13—100% | |
| Shares outstanding | 25—— | 25+239%— | 8.9+28.3%— | 8.0+15.3%— | 8.0+15.3%— | 7.5+10.9%— | 6.9+47.0%— | 6.9+48.3%— | 6.9+73.8%— | 6.8—— | 4.7—— | 4.7—— | 4.0—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2+6.3%58.8% | 0.1+1.2%226% | 0.1*+4.9%270% | 0.1*+9.0%446% | 0.1*+10.6%17.4% | 0.1+21.2%207% | 0.1*+17.9%116% | 0.0*+14.5%20.7% | 0.0*+14.9%53.5% | 0.0—122% | 0.0*—221% | 0.0*—137% | 0.0*—64.4% | |
| Share-based compensation | 1.6−42.5%449% | 0.3−85.6%1253% | 0.4*+155%2285% | 0.4+40.7%3389% | 0.5+44.5%155% | 2.0−0.9%8037% | 0.2*−88.0%406% | 0.3−81.0%122% | 0.3−78.2%364% | 2.0—5795% | 1.5*—7588% | 1.5r1.5—4865% | 1.5r1.5—2303% | |
| Cash from operating activities | −12—−3302% | −3.8—−16434% | −2.4*—−12322% | −2.9*—−24586% | −2.7*—−888% | −2.8—−11115% | −2.3*—−5422% | −1.7*—−728% | −1.9*—−2093% | −2.3—−6622% | −1.6r−1.8*—−8228% | −1.2r−1.2*—−3842% | −1.3r−1.1*—−1990% | |
| Capital expenditure | — | — | −0.1*—−406% | 0*—0.0% | 0*—0.0% | −0.0—−146% | −0.0*—−28.7% | −0.1*—−25.0% | — | — | −0.1*—−363% | −0.0*—−38.9% | −0.0*—−45.0% | |
| Cash from investing activities | 7.5−4.0%2095% | 1.0−59.1%4180% | 2.4*+56.6%12248% | 2.0*+113%16929% | 2.1*−28.3%703% | 2.4—9468% | 1.5*—3540% | 0.9*—401% | 3.0*+263%3337% | −4.9—−14080% | −0.1r0.1*—−439% | −0.0r−0.0*—−69.6% | 0.8r0.7*—1270% | |
| Shares issued | — | — | 1.1*—5536% | 0*—0.0% | 0.9*—306% | 1.1—4336% | — | — | — | — | 0.1r0*—430% | 0.0r1.4*—0.0% | — | |
| Shares bought back | — | 0—0.0% | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 6.2+551%1733% | 4.4+306%19166% | 0.9*—4710% | −0.0*—−418% | 0.9*—293% | 1.1−85.5%4371% | −0.1*−252%−292% | 0*−100%0.0% | −0.0*—−14.4% | 7.5—21481% | 0.1r0.1*—430% | 1.9*—6039% | — | |
| Change in cash | 1.9+2527%526% | 1.6+135%6912% | 0.9*—4636% | −1.0*—−8075% | 0.3*−70.2%108% | 0.7+150%2724% | −0.9*—−2174% | −0.8*−217%−327% | 1.1*—1229% | 0.3—779% | −1.6r−1.6*—−8237% | 0.7*—2128% | −0.1*—−81.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What BioRestorative Therapies, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$0 M83%+0.0%
- Royalty$0 M17%-40%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at BioRestorative Therapies, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 1 · Auditor changed 3 · Directors and officers 9 · Material agreement 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K/A | |
| Auditor changedDirectors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $1 M | Private placement after listing | Under $2 million | 16 | equity, options | SEC |
| Jan 2014 | $14 M | Private placement after listing | $10 to $50 million | 81 | equity, options | SEC |
| Apr 2012 | $2 M | No. 2 | Under $2 million | 6 | equity, debt, options | SEC |
| Nov 2010 | $1 M | No. 1 | Under $2 million | 15 | equity, debt | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at BioRestorative Therapies, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $71 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior QC AnalystBiological Technicians | 2 | $71 K |
Where: Melville, NY 2
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Biorestorative Therapies Inc.
How BioRestorative Therapies, Inc. compares in Healthcare
- Market cap$6 M · higher than 5% of 2,013
- Revenue$0 M · higher than 9% of 1,795
- Revenue growth-10.0% · higher than 21% of 1,003
- Price / sales16.7× · lower than 15% of 1,071
- Price / book16.7× · lower than 8% of 1,245
- FCF yield-181.8% · higher than 1% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BioRestorative Therapies, Inc.🇺🇸 | $6 M | — | — | -10.0% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BioRestorative Therapies, Inc.? Verify and update this profile — free
Show BioRestorative Therapies, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.